| Literature DB >> 31983359 |
S Yang1, Y Yu2, Y Ji3, D J Luo3, Z Y Zhang3, G P Huang3, F Y He3, W J Wu1, X P Mou3.
Abstract
Tuberculosis (TB) is the leading cause of death among infectious diseases. China has a high burden of TB and accounted for almost 13% of the world's cases of multi-drug resistant (MDR) TB. Spinal TB is one reason for the resurgence of TB in China. Few large case studies of MDR spinal TB in China have been conducted. The aim of this research was to observe the epidemiological characteristics of inpatients with MDR spinal TB in six provinces and cities of China from 1999-2015. This is a multicentre retrospective observational study. Patients' information was collected from the control disease centre and infectious disease database of hospitals in six provinces and cities in China. A total of 3137 patients with spinal TB and 272 patients with MDR spinal TB were analysed. The result showed that MDR spinal TB remains a public health concern and commonly affects patients 15-30 years of age (34.19%). The most common lesions involved the thoracolumbar spine (35.66%). Local pain was the most common symptom (98.53%). Logistic analysis showed that for spinal TB patients, reside in rural district (OR 1.79), advanced in years (OR 1.92) and high education degree (OR 2.22) were independent risk factors for the development of MDR spinal TB. Women were associated with a lower risk of MDR spinal TB (OR 0.48). The most common first-line and second-line resistant drug was isoniazid (68.75%) and levofloxacin (29.04%), respectively. The use of molecular diagnosis resulted in noteworthy clinical advances, including earlier initiation of MDR spinal TB treatment, improved infection control and better clinical outcome. Chemotherapy and surgery can yield satisfactory outcomes with timely diagnosis and long-term treatment. These results enable a better understanding of the MDR spinal TB in China among the general public.Entities:
Keywords: Anti-tubercular chemotherapy; drug resistance; epidemiology; spinal tuberculosis; surgery
Year: 2020 PMID: 31983359 PMCID: PMC7019620 DOI: 10.1017/S0950268820000011
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Demographic and clinical characteristics and logistic regression model analysis of variables associated with MDR spinal TB patients in this study
| Characteristics | ||||
|---|---|---|---|---|
| Spinal TB* | MDR spinal TB | OR (95% CI) | ||
| Sex | ||||
| Male | 1466 (51.17) | 187 (68.75) | 1.00 | − |
| Female | 1399 (48.83) | 85 (31.25) | 0.48 (0.37–0.62) | 0.00 |
| Age | ||||
| <14 | 145 (5.06) | 8 (2.94) | 0.64 (0.30–1.36) | 0.24 |
| 15–30 | 1089 (38.01) | 93 (34.19) | 0.99 (0.72–1.37) | 0.95 |
| 31–40 | 799 (27.89) | 69 (25.37) | 1.00 | − |
| 41–50 | 513 (17.91) | 47 (17.28) | 1.06 (0.72–1.56) | 0.77 |
| 51–60 | 205 (7.15) | 34 (12.5) | 1.92 (1.24–2.98) | 0.00 |
| >60 | 114 (3.98) | 21 (7.72) | 2.13 (1.26–3.61) | 0.00 |
| Region | ||||
| Urban | 936 (32.67) | 58 (21.32) | 1.00 | − |
| Rural | 1929 (67.33) | 214 (78.68) | 1.79 (1.33–2.42) | 0.00 |
| Education | ||||
| Primary | 973 (33.96) | 66 (24.26) | 0.74(0.55–1.00) | 0.05 |
| Middle | 1596 (55.71) | 146 (53.68) | 1.00 | − |
| University | 296 (10.33) | 60 (22.06) | 2.22 (1.60–3.07) | 0.00 |
| Neurological deficit | ||||
| Yes | 1009 (35.22) | 83 (30.51) | 1.00 | − |
| No | 1856 (64.78) | 189 (69.49) | 1.24 (0.95–1.62) | 0.12 |
| ESR (mm/h) | ||||
| Normal (<20) | 407 (14.21) | 29 (10.66) | 1.06 (0.70–1.60) | 0.78 |
| Moderate–elevated (20–100) | 2250 (78.53) | 151 (55.51) | 1.00 | − |
| High-elevated (>100) | 208 (7.26) | 92 (33.82) | 6.59 (4.90–8.86) | 0.00 |
MDR: multi-drug resistant; TB: tuberculosis; ESR: erythrocyte sedimentation rate.
*Spinal TB without MDR.
Clinical features at presentation (n = 272)
| Features | Number of patients (%) |
|---|---|
| Back pain | 268 (98.53) |
| Low fever or/and night sweats | 260 (95.59) |
| Local percussion pain | 257 (94.49) |
| Spinal activity limitation | 194 (71.32) |
| Kyphosis | 72 (26.47) |
| Skin ulceration or/and sinus formation | 53 (19.49) |
| Neurological symptoms | 83 (30.51) |
| Radicular pain | 49 (18.01) |
| Numbness | 43 (15.81) |
| Weakness | 36 (13.24) |
| Trouble walking | 28 (10.29) |
Characteristics of MDR spinal TB
| Patients (272) | Patients (3137) | ||
|---|---|---|---|
| % | % | ||
| MDR-STB | 272 | 100 | 8.67 |
| First-line drugs | |||
| Isoniazid | 187 | 68.75 | 5.96 |
| Rifampicin | 156 | 57.35 | 4.97 |
| Streptomycin | 114 | 41.91 | 3.63 |
| Second-line drug | |||
| Levofloxacin | 79 | 29.04 | 2.52 |
| Rifapentine | 62 | 22.79 | 1.98 |
| Amikacin | 23 | 8.46 | 0.73 |
| Kanamycin | 15 | 5.51 | 0.48 |
MDR: multi-drug resistant; TB: tuberculosis.
The first column represents the patients with MDR spinal TB (272); the second column represents all patients with spinal TB (3137). The data is the ratio of the number of patients with each drug resistance to the total number of patients. For example: 272/3137 = 8.67%; 187/272 = 68.75%; 187/3137 = 5.96%. Because each patient is resistant to two or more drugs, the sum of the number of patients who were resistant to each drug exceeds the total number (272).
Therapeutic outcome of MDR spinal TB patients diagnosed using conventional culture and molecular diagnosis technology (n = 272)
| Characteristic | Overall | Culture methods | Molecular diagnosis |
|---|---|---|---|
| Value | |||
| Treatment with first-line drug regimen | 272 (100) | 188 (69) | 84 (31) |
| Mean days on first-line drug* | 81 [14–434 d] | 154 [73–434 d] | 24 [14–38 d] |
| Mean days until starting treatment using second-line drug* | 44 [2–102 d] | 74[54–102 d] | 6 [2–7 d] |
| Mean days in drug-susceptible sickroom* | 19 [3–59 d] | 35[17–59 d] | 5 [3–7 d] |
| Mean days of drug treatment prior to hospitalisation* | 49 [13–108 d] | 84 [16–367 d] | 18 [13–31 d] |
| Mean days until hospitalisation and starting second-line drug pharmacotherapy* ( | 111 [31–365 d] | 128[31–365 d] | 75 [31–332 d] |
| Total days of hospitalisation* | 25 [11–59 d] | 34 [17–59 d] | 20 [11–34 d] |
| Required surgery* | 159 (58) | 114 (61) | 45 (54) |
| Recovered without need for surgery | 8 | 0 | 8 |
MDR: multi-drug resistant; TB: tuberculosis.
#: n = 138: MDR spinal TB patients started extramural hospital treatment using first-line drugs before their drug susceptibility test results were known.
*P < 0.05. Comparison between the culture methods group and molecular diagnosis group.
Treatment and follow-up outcomes of 272 MDR spinal TB patients in this study
| Treatment | ESR (mm/h) | VAS | ASIA ( | ||||
|---|---|---|---|---|---|---|---|
| A | B | C | D | E | |||
| Only chemotherapy ( | |||||||
| Prior treatment | 51.41 ± 23.42 | 5.46 ± 1.76 | 0 | 0 | 2 | 8 | 96 |
| Final follow-up | 5.93 ± 3.22* | 1.04 ± 0.98* | 0 | 0 | 0 | 5 | 101* |
| Chemotherapy + anterior approach ( | |||||||
| Pre-operation | 48.13 ± 27.45 | 5.71 ± 1.58 | 2 | 1 | 2 | 7 | 27 |
| 3 months postoperative | 6.93 ± 4.42* | 2.44 ± 0.78* | 0 | 0 | 2 | 1 | 36* |
| Final follow-up | 5.29 ± 3.03Δ | 0.47 ± 0.63Δ | 0 | 0 | 1 | 1 | 37 |
| Chemotherapy + posterior approach ( | |||||||
| Pre-operation | 50.53 ± 25.98 | 5.89 ± 1.68 | 3 | 0 | 7 | 25 | 33 |
| 3 months postoperative | 7.09 ± 4.23* | 2.66 ± 0.95* | 0 | 1 | 3 | 10 | 54* |
| Final follow-up | 5.88 ± 2.93Δ | 0.61 ± 0.63Δ | 0 | 0 | 2 | 2 | 64Δ |
| Chemotherapy + combined approach ( | |||||||
| Pre-operation | 46.79 ± 22.26 | 5.88 ± 1.91 | 5 | 0 | 5 | 16 | 26 |
| 3 months postoperative | 6.62 ± 4.61* | 2.67 ± 0.91* | 0 | 0 | 5 | 2 | 45* |
| Final follow-up | 5.71 ± 1.58 | 0.48 ± 0.60Δ | 0 | 0 | 4 | 1 | 47 |
| Chemotherapy + CT guided puncture ( | |||||||
| Pre-operation | 52.46 ± 25.34 | 5.88 ± 1.91 | 0 | 0 | 0 | 3 | 4 |
| 3 months postoperative | 7.14 ± 3.81* | 1.67 ± 0.79* | 0 | 0 | 0 | 1 | 6* |
| Final follow-up | 6.22 ± 4.11 | 1.27 ± 0.65 | 0 | 0 | 0 | 0 | 7 |
ESR: erythrocyte sedimentation rate, VAS: Visual Analogue Scale, ASIA: American Spinal Injury Association grading.
*P < 0.05 vs. pre-operation or prior treatment.
ΔP < 0.05 vs. 3 months postoperative.
Imaging findings and clinical treatment of MDR spinal TB
| Characteristic | |
|---|---|
| Site | 272 (100) |
| Cervical | 16 (5.88) |
| Cervicothoracic | 5 (1.84) |
| Thoracic | 97 (35.66) |
| Thoracolumbar | 43 (15.81) |
| Lumbar | 85 (31.25) |
| Lumbosacral | 26 (9.56) |
| Number of vertebrae involved | 272 (100) |
| 1–2 | 199 (73.16) |
| 3–4 | 54 (19.85) |
| ⩾5 | 19 (6.99) |
| Treatment | 272 (100) |
| Only Chemotherapy | 106 (38.97) |
| Chemotherapy + Local CT guided puncture | 7 (2.57) |
| Chemotherapy + Operation | 159 (58.46) |
| Drug-related complications | 21 (7.72) |
| Gastrointestinal symptoms | 13 (4.78) |
| Liver injury | 6 (2.21) |
| Peripheral nerve damage | 1 (0.37) |
| Hearing impairment | 1 (0.37) |
| Postoperative complications | 39 (24.53) |
| Sinus formation | 17 (10.69) |
| Delayed paralysis | 5 (3.14) |
| Incision disunion | 11 (6.92) |
| Instrumentation fracture | 2 (1.26) |
| Recurrence | 14 (8.81) |
| Local abscesses | 9 (5.66) |
| New abscesses at the non-surgical section | 5 (3.14) |
MDR: multi-drug resistant; TB: tuberculosis.
CT: computed tomography.